Previous reports have suggested that IL-17 signals through interactions with transmembrane receptors composed of IL-17RA and IL-17RC heterodimers induce a broad tissue response at the site of inflammation [12] and increase pro-tumor activity on tumor cells [18, 28]. The gene discussed is IL17A; the disease is neoplasm.